Trice Medical Achieves CE Mark and Health Canada Approval for Mi-Eye 2™

Register to receive a free U.S. Market Report Suite for Arthroscopic Devices – MedSuite report synopsis and brochure

U.S. based, Trice Medical, announced the completion of its first successful case performed in the United Kingdom, after receiving CE (Conformité Européenne) Mark of approval in Europe for the mi-eye 2™ hand-held arthroscope, as well as entry into Health Canada.

The case was performed by Mr. Tony Andrade, a Consultant Orthopaedic Surgeon at Circle Reading Hospital. “This is a fantastic opportunity to be able to show patients what’s going on inside their joints and talk them through it live as you see the pathology. This is something that’s been needed for a long time to aid patient’s understanding of their condition. It’s useful not just for diagnostic purposes, but it allows for the delivery of injections into the appropriate targeted area,” said Mr. Andrade.

The early success of Trice Medical’s mi-eye 2, which was launched in the U.S. in 2017, has captured the attention of medical professionals who are embracing the technology as a new diagnostic modality. After the first year of commercial launch, the mi-eye is currently being used by over 200 institutions across the states. The disposable needle embedded with a wide-angle camera lens enables physicians to diagnose joint injuries right in their clinic, and provide their patients with immediate answers to the cause of their pain.

“Truly disruptive technology always provides value by enhancing care and lowering cost. This approach to diagnosis is such a proposition,” stated Jon J.P. Warner, MD. Chief, MGH Shoulder Service and Professor of Orthopaedic Surgery at Harvard Medical School, regarding the mi-eye 2 technology.

“Trice is proud and excited to be commercializing the mi-eye 2 into Europe and Canada. MRI and Ultrasound will always be good options for patients with sports injuries. We are thrilled to add disposable in-clinic arthroscopy to the list of available tools physicians have to be able to assess joint injuries. In many countries, the mi-eye 2 has a chance to save weeks to months of the treatment pathway to surgery AND provide a dynamic image of the joint. The is truly an example of innovation in the new world of value-based medicine,” said Mark Foster, Chief Commercialization Officer and VP of Worldwide Sales at Trice Medical.

Additionally, Dr. Anthony Miniaci of the Cleveland Clinic Canada has completed the first cases performed by a surgeon in Toronto, ON. The advent of this technology in the Canadian market has the potential to provide patients with a dramatic amount of time saved in their overall continuum of care per injury.

The patient had this to say about her experience, “I had an operation back in December but was still having some knee problems. I didn’t want to go through another general anesthetic operation so Mr. Andrade recommended the mi-eye procedure would be a good option…The experience overall was fantastic, and I didn’t feel any pulling, tugging or pressure. Mr. Andrade has now identified what we need to do next for my treatment. I would definitely recommend it to others.”


For Further Information

More on the arthroscopic device market in the US can be found in a report published by iData Research entitled U.S. Market Report Suite for Arthroscopic Devices. The report covers the following market segments: arthroscopes, disposable cannulas, hand instruments, fluid management disposables, shaver blades, radiofrequency (RF) probes, drill guide systems and disposables and suture passers. Power instruments are covered in an appendix.

Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about arthroscopic device market data or procedure data, register online or email us at for a U.S. Market Report Suite for Arthroscopic Devices brochure and synopsis.

Leave a Reply